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patients ($1,042 vs. $1,593, p0.0034). The pharmacy costswere, however, higher in
these patients, compared to SOC-initiated patients ($4,358 vs. $3,235, p0.001). In
addition, duloxetine-initiated patients were less likely to use any opioids (56% vs.
63%, p0.05) compared with SOC patients not initiated on opioids. CONCLUSIONS:
Commercially-insured CLBP patients initiating duloxetine were associated with
significantly lower inpatient costs and CLBP-related outpatient costs, but higher
pharmacy costs, compared to patients initiating other SOC treatments. Duloxetine-
initiated patients were also less likely to use opioids in the post-index year.
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OBJECTIVES: The impact of on-demand (OD) treatment for bleeding episodes is
rarely quantified in Italian hemophilia patients with inhibitors. This study calcu-
lated lifetime events, hospitalizations, and quality-of-life (QoL) associated with
recombinant activated Factor VIIa (rFVIIa) and plasma-derived activated pro-
thrombin complex concentrate (pd-aPCC). This study also compared a hypotheti-
cal improved bypassing agent (BA) with faster, more sustained bleed resolution
than rFVIIa against pd-aPCC. METHODS: We developed an Italian semi-Markov
cohort model to reflect treatment effect on bleeds across a lifetime horizon for
2-year old hemophilia patients with high-responding inhibitors. The model tracks
patients through eight health states (pre-ITI, delayed ITI, ITI low dose, ITI high
dose, tolerized, partially-tolerized, non-tolerized, death) in 3-month cycles; bleeds
and treatment success are simulatedwithin states. Published international studies
informed efficacy estimates, and published utility data informed QoL parameter
values. RESULTS: In analysis of rFVIIa vs pd-aPCC, fewer rFVIIa patients required
1 series of home infusions per bleed (13% vs. 40% for pd-aPCC), leading to 4%
fewer hospitalizations following 2 unsuccessful home treatments. QALYs, de-
pendent on tolerization status in the basecase, are 43.13 for rFVIIa vs. 43.06 for
pd-aPCC. Exploratory comparison with improved rFVIIa bleed-resolution showed
reducing the rebleed rate by 15% reduces use of 1 line of therapy by 2%, decreas-
ing hospitalization 13% compared to basecase values. If fewer infusions of the new
BA are required to control a bleed per line of therapy, patients may experience QoL
benefits; utility improvement of 5%-20% raises total QALYs to 43.98-46.54 for the
new BA. CONCLUSIONS: rFVIIa may lower on-demand treatment resource use for
inhibitor patients in Italy, and improving haemostasis of BAs would further im-
prove patient care for this population; additional research around Italian treatment
patterns for inhibitor patients as well as the impact of faster bleed resolution is
warranted.
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OBJECTIVES:To systematically reviewpublished literature assessing the economic
evidence of biologic treatments indicated for Crohn’s disease (CD).METHODS: Pub-
lished articles between January 1995 and June 2011 were searched in PubMed,
EMBASE, ABI/INFORM, Tuft’s Cost-Effectiveness Analysis Registry Database, Co-
chraneNational Health Service Economic Evaluation Database, International Phar-
maceutical Abstracts, Web of Science, and Google Scholar. Studies of interest in-
cluded: 1) cost studies; 2) economic evaluations; or 3) narrative or systematic
reviews related to economic evaluations of biological treatments used for moder-
ate-to-severe CD. Exclusion criteria included the following characteristics: 1) CD-
related cost studies that were narrative or systematic reviews; 2) CD-related cost
studies that did not include costs of biologic treatments; 3) studies published only
as abstracts; or 4) non-English studies. The primary outcomes of interest included
costs associated with biological treatments and cost-effectiveness measures in-
cluding incremental cost-effectiveness ratios. A threshold value of $50,000/QALY
or £30,000/QALY was used to judge treatment cost-effectiveness. RESULTS: Twen-
ty-nine studies were identified, including 12 economic evaluations and 17 cost
studies or reviews of economic evaluations. Economic evaluation studies illus-
trated that infliximab was cost-effective compared with standard care for luminal
CD when provided as induction therapy followed by: 1) episodic therapy over 5 or
more years, or 2) maintenance therapy over one year. Additionally, adalimumab
was found to be more cost-effective than both infliximab and standard care for
luminal CD in terms of 1-year maintenance treatment with or without prior induc-
tion treatment. Cost studies revealed that infliximab usage reduced overall health-
care resource utilization and cost. Older reviews were inconclusive on the cost-
effectiveness of biologic treatments used for CD. CONCLUSIONS: Limited evidence
suggests that biologic treatments are cost-effective for CD under certain clinical
situations. Future studies are recommended to include all indicated biologic treat-
ments to provide a systematic comparison regarding their comparative benefits
and costs.
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OBJECTIVES: This retrospective study aimed to estimate the economic burden
associated with WPL in patients with psoriasis (Pso) in a US based population.
METHODS: Continuously enrolled adult patients with 2 Pso diagnoses were se-
lected from the MarketScan Claims database (2004-2008). Pso patients were
matched (based on age and gender) to continuously enrolled adult Pso-free pa-
tients (i.e., without diagnosis for Pso or psoriatic arthritis). WPL was estimated
using workplace absenteeism and short term disability (STD) expenditures avail-
able in the MarketScan Health and Productivity Management database. Only patients
for whom the employer recorded absenteeism and STD were included in the anal-
ysis. WPL, often referred to as total indirect cost, was defined as the sum of absen-
teeism costs (i.e., hours out of work for medical reasons [sick leave]* hourly wage)
and STD costs (number of days on disability * daily wage). Wages were imputed
based on the regions of residence using data from the U.S. Bureau of Labor Statis-
tics. Annual incremental costs associated with WPL in Pso patients were stratified
by Pso severity (mild or moderate-to-severe) and estimated using generalized lin-
ear models. Moderate-to-severe Pso patients were defined as patients who used
systemic therapies during the 6-month baseline period; mild Pso patients did not
use any systemic therapies during the baseline period. RESULTS: A total of 1137
matched pairs were included. Among Pso patients, 305 (26.8%) had moderate-to-
severe Pso. After adjusting for confounding factors (age and gender), no significant
cost differences associated with WPL were found when comparing mild Pso to
Pso-free patients ($1827 for mild Pso vs. $1770 for Pso-free; difference $52,
p0.825). When compared to Pso-free patients, however, moderate-to-severe Pso
patients were associated with significant incremental WPL of $1026 per patient-
year ($2781 for moderate-to-severe Pso vs. $1770 for Pso-free; p0.014).
CONCLUSIONS: Pso imparts a substantial WPL in patients with moderate-to-se-
vere Pso.
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OBJECTIVES: To estimate incremental resource use and costs of Pso and obesity in
Pso patients.METHODS: Adult Pso patients (2 Pso diagnoses) were selected from
a large US claims database (2004-2008). Pso patients were matched (based on age
and gender) to Pso-free patients (i.e., without Pso or psoriatic arthritis diagnosis).
Obesity was defined based on patients’ reported body mass index (BMI30).
Healthcare resource use and costs were assessed over a one-year period. Incidence
rate differences and incremental annual total health care costs (USD 2010; mea-
sured from a payer perspective) associated with Pso and obesity between Pso and
Pso-free patients were estimated using multivariate Poisson regression models
and generalized linear regressionmodels, respectively, controlling for age, gender,
and Charlson comorbidity index. RESULTS: A total of 1874 matched pairs with
reported BMI were selected. Among Pso patients, 34%were obese compared to 28%
of the Pso-free controls (p0.01). Compared to non-obese Pso patients, obese Pso
patients had on average 7more urgent care visits (hospitalizations and emergency
department visits) per 100 patient-years (p 0.02), and 1.8 more outpatient visits
per patient-years (p0.01). Compared to Pso-free patients, Psowas associatedwith
5.0 more outpatients visits per patient-years in non-obese patients and 6.3 more
outpatients visits per patient-year in obese patients (both p 0.01). Among Pso
patients, obesity presented a $2,729 incremental cost compared to the non-obese
Pso patients ($12,670 vs. $9,192; p0.01). Compared to Pso-free patients, Pso was
associated with a $4,735 incremental total health care cost among non-obese pa-
tients ($9,192 vs. $4,681; p0.01) and a $6,887 incremental cost among obese pa-
tients ($12,670 vs. $5,460; p0.01). The difference ($2152) between $6887 and $4735
was not statistically significant in the final model. CONCLUSIONS: Pso patients
have higher prevalence of obesity when compared to Pso-free patients. Both Pso
and obesity were associated with significant incremental costs.
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OBJECTIVES: Patients with FLT3-mutated AML have poor prognoses due to short
survival, high incidence of relapse, and a lack of effective treatment options. The
objective of this study was to review AML-related literature and estimate the eco-
nomic burden of FLT3-mutated AML in the United States.METHODS: A systematic
literature review was conducted to identify relevant publications from 2000-2011.
Estimates of the epidemiology of FLT3-mutated AML were calculated from SEER
data andUS Census projections. An Excelmodel was developed to estimate the BOI
of FLT3-mutated AML. Resource utilization estimates were obtained from the lit-
erature and expert opinion. RESULTS:A total of 607 citationswere identified and 35
articles abstracted. No direct estimates for the incidence or prevalence of FLT3-
mutated AML in the United States were identified in the literature. The prevalence
of AML in 2008 was obtained from SEER data (27,813 patients aged 20 years). In
2010, it was estimated that 784 adults 60 years and 1,622 adults 60 years were
diagnosed with FLT3-mutated AML. The BOI of FLT3-mutated AML in the US was
estimated at $251 million in 2010, including $191 million in direct costs and $60
million in lost productivity. For newly diagnosed patients60 years, the burden of
FLT3-mutated AMLwas estimated at $90million in 2010. Inpatient hospitalizations
accounted for 36% of direct costs and stem cell transplants for 38%. The cost per
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